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Increases in our understanding of the molecular control of circadian rhythms and subsequent signaling
pathways has allowed for new therapeutic drug targets to be identiﬁed as well as for a better understand-
ing of how to more efﬁcaciously and safely utilize current drugs. Here, we review recent advances in tar-
geting components of the molecular clock in mammals for the development of novel therapeutics as well
as describe the impact of the circadian rhythm on drug efﬁcacy and toxicity.
 2013 Published by Elsevier Ltd. Open access under CC BY-NC-ND license.Most, if not all light-sensitive organisms, including mammals, pacemaker located in the superchiasmatic nucleus (SCN) of the
possess a master circadian clock that regulates physiological and
behavioral processes in alignment with the 24-h day. Recent ad-
vances in understanding the molecular control of circadian
rhythms and subsequent signaling pathways has allowed for new
therapeutic targets to be identiﬁed as well as for a better under-
standing of how tomore efﬁcaciously utilize current drugs. In addi-
tion to playing a key role in normal physiology and behavior,
aberrations in the circadian rhythm are associated with the patho-
physiology of diseases including diabetes, cardiovascular disease,
psychological disorders and various autoimmune diseases/inﬂam-
mation.1–5 Additionally, the potency and efﬁcacy of many drugs is
associated with the circadian rhythmicity of expression of their
molecular targets and cellular biochemical signals.4 A signiﬁcant
fraction of genes are expressed in a circadian fashion6 including
many drug targets and drug metabolizing enzymes yielding poten-
tial differences in efﬁcacy/side effects based on time of day admin-
istration. Applying the knowledge of circadian function and
regulation to the relevance of disease has enabled a chronotherapy
approach in the timing of administration of conventional drugs in
order to synchronize the rhythms in disease activity with the efﬁ-
cacy of the drug. Furthermore, recent advances in targeting the
protein components involved in maintenance of the core circadian
rhythm have allowed us to examine pharmacological alteration of
the core rhythm to examine potential utility for treatment of
disease.
Circadian rhythms inﬂuence most, if not all of mammalian
physiology. Optimizing and coordinating metabolic processes, cel-
lular functions and the organism’s behavior including the sleep-
wake cycle can be viewed as the main tasks of the circadian timing
system (CTS).2 The CTS is hierarchical in structure with the masterhypothalamus. This master pacemaker coordinates countless
peripheral clocks within various tissue and cell types. In general,
the molecular makeup of oscillators within the SCN and the
periphery are very similar, with the main difference being how
they are synchronized and inﬂuenced by various signals. The SCN
is entrained by light received by the retina while the peripheral
oscillators are often adjusted by chemical signals or by feed-
ing2,7–9 (Fig. 1).
Feedback regulation on a transcriptional and posttranscrip-
tional level creates and maintains the circadian oscillations in the
context of a single cell. Heterodimers of transcription factors,
either CLOCK or NPAS2 with BMAL1 bind to DNA E-box elements
within enhancer and promoter regions of the Cryptochrome (Cry)
and Period (Per) genes and stimulate their transcription. CRY and
PER protein levels accumulate to form complexes that inhibit the
BMAL1-CLOCK/NPAS2 heterodimers, leading to the loss of activa-
tion of Cry and Per genes, and a reduction of CRY and PER protein
levels which leads to the next transcriptional cycling event.2,10,11
Additionally, BMAL1–CLOCK/NPAS2 heterodimers also drive the
circadian expression of REV-ERB, an nuclear receptor that re-
presses both Bmal1 and Clock gene transcription by direct binding
to their promoters12–14 (Fig. 2). An additional nuclear receptor, the
retinoic acid receptor-related orphan receptor (ROR) also plays an
important role activating transcription of the Bmal1 gene by bind-
ing to the identical DNA response element recognized by REV-
ERB.15–17 Other proteins such as the WD40 protein, NONO DNA-
binding protein, the WDR5 histone methyl transferase binding
platform, and casein kinases (CK1) also play an important role in
modulation of the feedback loop ensuring proper circadian func-
tion.2,18 This self-sustained, cell autonomous circadian oscillator
is maintained in most, if not all mammalian cells19 and drives
physiological alterations by controlling genes that are responsive
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Figure 1. Circadian clocks exist both in the central nervous system and in the peripheral tissues. The ﬁgure illustrates the master clock (suprachiasmatic nucleus (SCN)) is via























Figure 2. The mammalian circadian clock. (a) The mechanism of the mammalian molecular clock illustrating the feedback loop that maintains 24-h oscillations of BMAL1-
CLOCK/NPAS2 and PER-CRY expression. (b) Illustration of antiphase circadian oscillations of BMAL1-CLOCK/NPAS2 and PER-CRY expression. (c) Schematic illustrating the
relationship between the core clock and clock-controlled genes.
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clearly ‘druggable’ and very recent studies have demonstrated the
effects of modulating the activity of these targets on circadian
physiology as well as pathological states. The nuclear receptor
REV-ERB was recently deorphanized and heme was identiﬁed as
the physiological ligand20,21 and these studies clearly suggested
that synthetic compounds could directly target this nuclear recep-
tor. Our group recently developed synthetic agonists for REV-ERB,
SR9009, that demonstrated the ability to modulate circadianbehavior as well as metabolism3 (Fig. 3). Administration of REV-
ERB agonists in mice resulted in alterations in the expression of
clock genes both in the SCN and the periphery (liver, adipose and
skeletal muscle). Circadian wheel running behavior was altered
and interestingly, mice displayed increased energy expenditure
with no increase in locomotion or food intake. Additionally, when
administered to diet-induced obese mice, REV-ERB agonist SR9009
induced signiﬁcant weight loss (fat mass) and reduced plasma tri-






























Figure 3. Synthetic compounds that modulate the clock. Chemical structures of several compounds that alter the circadian rhythm by targeting the core clock are shown.
LH846 and longdaysin are CK1 inhibitors while indirubin is a GSK3b inhibitor. SR9009 is a REV-ERB agonist and KL001 is an activator of CRY.
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disorders. A number of synthetic ligands that target the ROR nucle-
ar receptors have also been recently identiﬁed; however, their abil-
ity to modulate the circadian rhythm has not yet been
examined.22–27
Small molecule activators of the CRY proteins were recently
identiﬁed using a cell-based circadian phenotypic screen.28
KL001 interacts speciﬁcally with CRY and prevents its ubiquitin-
dependent degradation leading to lengthening of the circadian per-
iod in cell-based models28 (Fig. 3). Additionally, KL001 modulation
of CRY stability led to inhibition of glucagon-induced gluconeogen-
esis in primary hepatocytes providing further evidence that target-
ing the clock may hold utility in the treatment of metabolic
disorders. No studies with KL001 or related compounds have been
performed in vivo yet.
The CK1 family of kinases has been implicated in the phosphor-
ylation of PER proteins and modulation of their activity. CK1d has
been implicated as the dominant isozyme required for regulation
of the circadian period based on studies with isozyme selective
CK1 inhibitors.29 Longdaysin, an inhibitor of CK1a, CK1d and extra-
cellular signal-regulated kinase 2 (ERK2), was identiﬁed in a screen
of compounds based on their ability to lengthen the circadian per-
iod and this compound appears to function via stabilization of
PER130 (Fig. 3). Administration of longdaysin to zebraﬁsh resulted
in a lengthened circadian period. Other CK1d inhibitors such as
LH846 have also been identiﬁed and have the ability to lengthen
the circadian period in cell based models31 (Fig. 3). In contrast to
the CK1d inhibitors, inhibitors of glycogen synthase kinase b
(GSK3b), such as indirubin, appear to shorten the circadian peri-
od32 (Fig. 3). GSK3b substrates include several components of the
clock including REV-ERB, BMAL1, CLOCK and CRY2, thus it is not
clear exactly how these compounds mechanistically alter the clock.
Clearly, there appear to be multiple opportunities to develop small
molecule modulators of clock components and employ a chemical
biology approach to determine the potential therapeutic utility of
such compounds.Variations in gene expression due to circadian changes often
have effects on the absorption, distribution, metabolism and elim-
ination of drugs2 (Fig. 4). These effects result from the rhythmic
changes in liver metabolism, membrane viscosity, blood ﬂow in
the periphery as well as through organs, renal ﬁltration rates,
and various other rhythmic physiological properties. Clearly, efﬁ-
cacy and tolerability of a drug can be severely impacted by circa-
dian pharmacokinetics and pharmacodynamics.
One of the most extensively studied examples of time-depen-
dent dosing on drug effect and toxicity is glucocorticoid receptor
(GR) agonists. GR is a ubiquitously expressed, glucocorticoid-acti-
vated member of the nuclear receptor superfamily of transcription
factors and is involved in the regulation of development, metabo-
lism, and immune response. The natural ligands for GR are gluco-
corticoids, predominantly cortisol, and are synthesized from
cholesterol precursors in the adrenal cortex under tight regulation
from hypothalamo-pituitary axis. Circulating levels of glucocorti-
coids ﬂuctuate in a circadian manner, with the highest levels ob-
served in the morning and the lowest levels in the late evening
in diurnal animals. Two decades ago, Beam et al. described a rela-
tionship between time of day of administration of a synthetic GR
agonist, prednisone, and relief of nocturnal worsening of asthma
symptoms.33 They speculated that the worsening of asthmatic
symptoms at night was related to the corticosteroid-sensitive cir-
cadian localization of eosinophils to the lungs.33 Subjects were
treated with oral prednisone at one of several time points (0800,
1500, and 2000 h) for six weeks and monitored by bronchoscopy,
spirometry, and blood eosinophil levels. Interestingly the timing
of prednisone was absolutely critical for the relief of the nocturnal
worsening of the symptoms and the 1500 h administration of
prednisone was effective while dosing at either 0800 h or 2000 h
was ineffective.33
More recently GR function has been shown to be closely linked
to the mammalian clock. The CLOCK/BMAL1 complex directly
interacts and enzymatically targets GR, thereby regulating the ac-
tion of its ligands in peripheral tissues.34 It was suggested that
Figure 4. Schematic illustrating the role of the clock in regulation of oscillations in various enzymes and drug target expression levels that lead to variability in drug efﬁcacy,
pharmacokinetics and toxicity with regard to the time of day administration of a drug.
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the GR hinge region and suppresses transcriptional activity regu-
lated by GR, indicating that components of the circadian clock
can modulate the effects of glucocorticoids on immune functions
in various tissues and organs.34 Studies in Per2/Cry1 knockout
mice, which lack a circadian rhythm, displayed defective pituitary
and adrenal regulation. Interestingly, tissue transplantation in
these mice led to a rescued glucocorticoid rhythm under LD condi-
tions.35 Most recently it was demonstrated that CRY1 and CRY2 di-
rectly interact with GR and modulate the ligand-dependent
activity of the receptor suggesting another direct link between
GR function and a core component of the mammalian clock.36
Many anticancer therapeutics have been shown to exhibit dif-
fering effects and toxicity based on administration time in ro-
dents.37,38 Gorbacheva et al. showed the clear relationship
between the chemotherapeutic agent, cyclophosphamide, and
functional timing of the CLOCK/BMAL1 circadian components.37
Several different mutant mouse models were used to explore the
molecular link between in vivo cyclophosphamide drug toxicity
and circadian function, when compared to control mice treated
with the same drug. It was observed that animals treated at the
dark:light transition were more sensitive to drug toxicity than
those treated at the light:dark transition; the increased drug sensi-
tivity also appeared to correlate with survival of the animals37
Clock mutants and Bmal1/ mice also showed a severe reduction
in body weight following cyclophosphamide treatment, whereas
the control mice maintained a stable body weight following injec-
tions. These ﬁndings suggested that when CLOCK/BMAL1 activity is
deﬁcient mice display a higher sensitivity to the chemotherapeutic
drug. In addition, this and several other groups hypothesized that
the circadian regulation of drug sensitivity may be further con-
trolled by peripheral clocks regulating the rhythmic activity of
drug-metabolizing enzymes, and not solely through the CLOCK/
BMAL1 transactivation pathway in the SCN.2,37,39
Since many of the components of the detoxiﬁcation system
have circadian mRNA expression, it makes sense that toxicity of
certain drugs depends on the time of dosing. Members of cyto-
chrome p450 (CYP) family of drug-metabolizing enzymes are
highly expressed in the liver, kidney, intestine, and other organs.
These enzymes often have oxidase, reductase, or hydrolase activi-
ties that aid in the removal of toxins.2 Additionally, conjugating en-
zymes, like sulfonotransferases, modify lipophillic components of
drugs and allow for excretion into bile or urine. Most enzymes
within the detoxiﬁcation pathway have been shown to display cir-
cadian ﬂuctuation throughout the day that likely contribute to
time-dependent efﬁcacy of speciﬁc drugs.2 An additional compo-
nent of the molecular basis of detoxiﬁcation involves several nu-
clear receptors including constitutive androstane receptor (CAR),pregnane X receptor (PXR), peroxisome proliferator-activated
receptor (PPAR), liver X receptor (LXR), farnesoid X receptor
(FXR), and hepatocyte nuclear factor (HNF4), and other transcrip-
tional regulatory proteins like the aryl hydrocarbon receptor
(AHR).2,40 Several of these proteins regulate the detoxiﬁcation sys-
tem in a circadian manner as they either accumulate in a circadian
manner or themselves display a circadian rhythm.2 Various studies
suggest that the circadian expression of many nuclear receptors
may shed light on how circadian rhythms are linked to disease
and also how to effectively treat an individual.8,40–42 Iwata et al.
using the broad-spectrum anti-cancer drug gemcitabine (GEM) re-
cently described an example of this.42 Several studies revealed that
standard weekly treatments of GEM often led to unpleasant side
effects including myelosuppression, nausea, vomiting, alopecia,
and varying hematologic toxicity in patients.18,39,42 Patients were
randomly divided into two groups, either receiving treatment at
9 am or 3 pm, and the difference between hematologic toxicity be-
tween the groups over a two-week period.42 In addition to deter-
mining changes in white blood cell counts, red blood cell,
hematocrit, hemoglobin and other serum levels were also assessed.
This group was able to show that dosing with GEM earlier in the
day alleviated hematologic toxicity. This is likely due to the rapid
metabolism of GEM in the liver, kidneys, and plasma by cytidine
deaminase, which has circadian expression in humans and peaks
during the early active phase.42 Interestingly, studies of GEM in
mice also show that circadian expression of BAX and BCL-2 may
also contribute to the tolerability of this drug, since it targets S-
phase cells and promotes apoptosis.42
In a recent study, Hamdan et al. found that the Abcg2 intestinal
gene expression in mice is under the circadian control of the ATF4-
CLOCK pathway and further investigated how ﬂuctuations in gene
expression affected oral absorption of a classic substrate of the
breast cancer resistance protein (BCRP) in vivo.43 The well-charac-
terized BCRP substrate sulfasalazine was orally administered to
Abcg2 knockout demonstrating a 10-fold increase in accumulation
than in wildtype mice. Interestingly, in the wildtype mice, intesti-
nal accumulation of sulfasalazine displayed a circadian rhythm
antiphase to that of BCRP expression.43 It has been speculated that
BCRP expression in the mouse intestine is regulated by peripheral
clocks and regulates the rate of intestinal drug absorption. It
should also be mentioned that alternative routes of drug adminis-
tration, including oral, cutaneous/transdermal, and intravenous,
have differences in drug absorption rates inﬂuenced by circadian
rhythms.4 It has been demonstrated previously that local anes-
thetic agents have varying penetration rates through the skin in
a circadian time-dependent manner.4,44,45 Therefore, drug formula-
tion, route of administration and circadian rhythms inﬂuences
should all be taken into account when treating a disease.4,44,45
K. Griffett, T. P. Burris / Bioorg. Med. Chem. Lett. 23 (2013) 1929–1934 1933Taken together, the studies mentioned thus far suggest a molecular
link between circadian rhythms and drug pharmacology that
should be exploited in future therapeutic studies.
Another consideration when thinking about the chronopharma-
cology of a drug or compound is the delivery of treatment to a pa-
tient based on the dynamic disease-speciﬁc pathology and the
changes in the pharmacology of that particular drug, often referred
to as chronotherapeutics.2,40,46 This relatively new discipline of
medical treatment allows for the consideration of a patient’s bio-
logical rhythm, changes in the severity of a disease state during
the day, and the synchronizing of dosing and delivery of a particu-
lar drug to allow for the optimal efﬁcacy in the patient.46,47 Many
studies have shown that cardiovascular related events, such as
myocardial infarction and stroke, often occur in the early morning
due to circadian changes regulating blood pressure, heart rate,
vasodilating hormones, etc.47,48 Dihydropyridine calcium channel
blockers, such as Norvasc, have been shown that time of day dos-
ing, particularly evening, is the most advantageous for efﬁcacy of
the treatment and normalizing changes in blood pressure rhythms
to reduce early morning cardiac events.47,48 ACE inhibitors, AT-
receptor blockers, diuretics, and other antihypertensives have also
been studied to determine circadian-based time of day dosing for
the most effective treatment.
While many people acknowledge that targeting diseases with
speciﬁc time-of-day dosing of drugs based on circadian rhythms
is beneﬁcial for patients in increasing efﬁcacy while reducing side
effects, it is often overlooked that disruption of circadian rhythms
can lead to disease. Disruption of circadian rhythms is often ob-
served in individuals involved with shift-work or sudden changes
in time schedule from traveling (jet-lag), and often contribute to
ﬂuctuations in sleep patterns, behaviors, and metabolic patterns.
In the case of jet-lag, circadian disruption is temporary but often
leads to feelings of general discomfort, irritability, depression, gas-
trointestinal upset, and a decreased mental and physical perfor-
mance.49,50 Similar to individuals with jet-lag, shift workers tend
to have circadian disruption of the master and peripheral clocks,
leading to an increased incidence of gastrointestinal, cardiovascu-
lar, and metabolic diseases, as well as menstrual problems in wo-
men, and increased cancer risks.49 It should also be noted that
even low-intensity light exposure at night can disrupt the clock
in humans, which often alters temperature and hormonal rhythms
and may lead to an increased disease propensity.49,51 An interest-
ing study performed by Cheeseman et al. tested the effects of gen-
eral anesthesia on time perception and circadian rhythm in
honeybees.52 Honeybees have a remarkably similar genetic and
functional molecular circadian network to mammals and this work
demonstrated that isoﬂurane exposure, a general anesthetic, led to
abnormal orienting behavior, alterations in foraging time, atypical
circadian rhythms, and severely altered circadian gene expression
markers. It was also demonstrated that the phase shifting caused
by the use of isoﬂurane was in direct contrast with those caused
by pulsed light. When isoﬂurane or pulsed light was administered
during daytime, a strong phase delay was observed for the isoﬂu-
rane treated bees but not the light-treated bees. Conversely, when
administered at night, only the light treatment caused a phase de-
lay in the bees.52 These results suggest a possible neurobiological
mechanism that may be shifting the circadian clock in honeybees
and can be extrapolated to circadian shifts and time perception
in mammals following anesthesia administration. An important
question to consider is whether it may be possible to target the cir-
cadian mechanisms in order to treat patients and help expedite
recovery time following surgical procedures.52
It is clear that environmental cues drive the rhythmic expres-
sion of clock genes in mammals. Many physiological processes in
humans are inﬂuenced by both the CTS of the master clock in the
SCN and various peripheral clocks found in differing tissues. Recentstudies have begun to decipher the molecular networks involved in
the regulation and coordination of these clocks, and thus further-
ing the understanding of how circadian timing affects physiologi-
cal processes and disease development. The latest advances in
chronopharmacology are leading the way to unleash new opportu-
nities for drug discovery and advance drug development. As men-
tioned previously, it has been shown that circadian rhythms
inﬂuence how drugs are absorbed, distributed, metabolized, and
eliminated from the body. Development of circadian-controlled re-
lease and/or delivery of current therapeutics may enhance treat-
ment efﬁcacy and control cell toxicity, especially in
chemotherapeutic agents. Further research should be applied to
optimizing novel drugs to synchronize with a patient’s circadian
rhythm, in order to increase the beneﬁt of treatment.53 Addition-
ally, the development of drugs that act by speciﬁcally modulating
the components of the circadian clock is another highly anticipated
area of chronopharmacology.
References and notes
1. Rybak, Y. E.; McNeely, H. E.; Mackenzie, B. E.; Jain, U. R.; Levitan, R. D. Compr.
Psychiatry 2007, 48, 562.
2. Levi, F.; Schibler, U. Annu. Rev. Pharmacol. Toxicol. 2007, 47, 593.
3. Solt, L. A.; Wang, Y.; Banerjee, S.; Hughes, T.; Kojetin, D. J.; Lundasen, T.; Shin,
Y.; Liu, J.; Cameron, M. D.; Noel, R.; Yoo, S.-H.; Takahashi, J. S.; Butler, A. A.;
Kamenecka, T. M.; Burris, T. P. Nature 2012, 485, 62.
4. Ohdo, S. Biol. Pharm. Bull. 2010, 33, 159.
5. Sprouse, J. Expert Opin. Ther. Targets 2004, 8, 25.
6. Yan, J.; Wang, H.; Liu, Y.; Shao, C. PLoS Comput. Biol. 2008, 4, e1000193.
7. Dallmann, R.; Viola, A. U.; Tarokh, L.; Cajochen, C.; Brown, S. A. Proc. Natl. Acad.
U.S.A. 2012, 109, 2625.
8. Iurisci, I.; Filipski, E.; Sallam, H.; Harper, F.; Guettier, C.; Maire, I.; Hassan, M.;
Iacobelli, S.; Levi, F. Chronobiol. Int. 2009, 26, 1169.
9. Langmesser, S.; Albrecht, U. Chronobiol. Int. 2006, 23, 151.
10. Albrecht, U. J. Physiol. Paris 2006, 100, 243.
11. Mohawk, J. A.; Green, C. B.; Takahashi, J. S. Annu. Rev. Neurosci. 2012, 35, 445.
12. Guillaumond, F.; Dardente, H.; Giguere, V.; Cermakian, N. J. Biol. Rhythms 2005,
20, 391.
13. Crumbley, C.; Burris, T. P. PLoS ONE 2011, 6, e17290.
14. Preitner, N.; Damiola, F.; Molina, L. L.; Zakany, J.; Duboule, D.; Albrecht, U.;
Schibler, U. Cell 2002, 110, 251.
15. Akashi, M.; Takumi, T. Nat. Struct. Mol. Biol. 2005, 12, 441.
16. Burris, T. P. Mol. Endocrinol. 2008, 22, 1509.
17. Sato, T. K.; Panda, S.; Miraglia, L. J.; Reyes, T. M.; Rudic, R. D.; McNamara, P.;
Naik, K. A.; Fitzgerald, G. A.; Kay, S. A.; Hogenesch, J. B. Neuron 2004, 43, 527.
18. Levi, F.; Filipski, E.; Iurisci, I.; Li, X. M.; Innominato, P. Cold Spring Harb. Symp.
Quant. Biol. 2007, 72, 465.
19. Nagoshi, E.; Saini, C.; Bauer, C.; Laroche, T.; Naef, F.; Schibler, U. Cell 2004, 119,
693.
20. Raghuram, S.; Stayrook, K. R.; Huang, P.; Rogers, P. M.; Nosie, A. K.; McClure, D.
B.; Burris, L. L.; Khorasanizadeh, S.; Burris, T. P.; Rastinejad, F. Nat. Struct. Mol.
Biol. 2007, 14, 1207.
21. Yin, L.; Wu, N.; Curtin, J. C.; Qatanani, M.; Szwergold, N. R.; Reid, R. A.; Waitt, G.
M.; Parks, D. J.; Pearce, K. H.; Wisely, G. B.; Lazar, M. A. Science 2007, 318, 1786.
22. Wang, Y.; Kumar, N.; Nuhant, P.; Cameron, M. D.; Istrate, M. A.; Roush, W. R.;
Grifﬁn, P. R.; Burris, T. P. ACS Chem. Biol. 2010, 1029.
23. Kumar, N.; Kojetin, D. J.; Solt, L. A.; Kumar, K. G.; Nuhant, P.; Duckett, D. R.;
Cameron, M. D.; Butler, A. A.; Roush, W. R.; Grifﬁn, P. R.; Burris, T. P. ACS Chem.
Biol. 2011, 6, 218.
24. Solt, L. A.; Kumar, N.; Nuhant, P.; Wang, Y. J.; Lauer, J. L.; Liu, J.; Istrate, M. A.;
Kamenecka, T. M.; Roush, W. R.; Vidovic, D.; Schurer, S. C.; Xu, J. H.; Wagoner,
G.; Drew, P. D.; Grifﬁn, P. R.; Burris, T. P. Nature 2011, 472, 491.
25. Kumar, N.; Lyda, B.; Chang, M. R.; Lauer, J. L.; Solt, L. A.; Burris, T. P.;
Kamenecka, T. M.; Grifﬁn, P. R. ACS Chem. Biol. 2012, 7, 672.
26. Solt, L. A.; Kumar, N.; He, Y.; Kamenecka, T. M.; Grifﬁn, P. R.; Burris, T. P. ACS
Chem. Biol. 2012, 7, 1515.
27. Huh, J. R.; Leung, M. W. L.; Huang, P. X.; Ryan, D. A.; Krout, M. R.; Malapaka, R.
R. V.; Chow, J.; Manel, N.; Ciofani, M.; Kim, S. V.; Cuesta, A.; Santori, F. R.;
Lafaille, J. J.; Xu, H. E.; Gin, D. Y.; Rastinejad, F.; Littman, D. R. Nature 2011, 472,
486.
28. Hirota, T.; Lee, J. W.; John, P. C.; Sawa, M.; Iwaisako, K.; Noguchi, T.;
Pongsawakul, P. Y.; Sonntag, T.; Welsh, D. K.; Brenner, D. A.; Doyle, F. J., 3rd;
Schultz, P. G.; Kay, S. A. Science 2012, 337, 1094.
29. Meng, Q. J.; Maywood, E. S.; Bechtold, D. A.; Lu, W. Q.; Li, J.; Gibbs, J. E.; Dupre,
S. M.; Chesham, J. E.; Rajamohan, F.; Knafels, J.; Sneed, B.; Zawadzke, L. E.;
Ohren, J. F.; Walton, K. M.; Wager, T. T.; Hastings, M. H.; Loudon, A. S. Proc. Natl.
Acad. Sci. U.S.A. 2010, 107, 15240.
30. Hirota, T.; Lee, J. W.; Lewis, W. G.; Zhang, E. E.; Breton, G.; Liu, X.; Garcia, M.;
Peters, E. C.; Etchegaray, J. P.; Traver, D.; Schultz, P. G.; Kay, S. A. PLoS Biol. 2010,
8, e1000559.
1934 K. Griffett, T. P. Burris / Bioorg. Med. Chem. Lett. 23 (2013) 1929–193431. Lee, J. W.; Hirota, T.; Peters, E. C.; Garcia, M.; Gonzalez, R.; Cho, C. Y.; Wu, X.;
Schultz, P. G.; Kay, S. A. Angew. Chem., Int. Ed. 2011, 50, 10608.
32. Reischl, S.; Kramer, A. FEBS Lett. 2011, 585, 1393.
33. Beam, W. R.; Weiner, D. E.; Martin, R. J. Am. Rev. Respir. Dis. 1992, 146, 1524.
34. Nader, N.; Chrousos, G. P.; Kino, T. FASEB J. 2009, 23, 1572.
35. Oster, H.; Damerow, S.; Kiessling, S.; Jakubcakova, V.; Abraham, D.; Tian, J.;
Hoffmann, M. W.; Eichele, G. Cell Metab. 2006, 4, 163.
36. Lamia, K. A.; Papp, S. J.; Yu, R. T.; Barish, G. D.; Uhlenhaut, N. H.; Jonker, J. W.;
Downes, M.; Evans, R. M. Nature 2011, 480, 552.
37. Gorbacheva, V. Y.; Kondratov, R. V.; Zhang, R.; Cherukuri, S.; Gudkov, A. V.;
Takahashi, J. S.; Antoch, M. P. Proc. Natl. Acad. Sci. U.S.A. 2005, 102, 3407.
38. Dibner, C.; Schibler, U.; Albrecht, U. Annu. Rev. Physiol. 2010, 72, 517.
39. Levi, F.; Okyar, A.; Dulong, S.; Innominato, P. F.; Clairambault, J. Annu. Rev.
Pharmacol. Toxicol. 2010, 50, 377.
40. Levi, F.; Focan, C.; Karaboue, A.; de la Valette, V.; Focan-Henrard, D.; Baron, B.;
Kreutz, F.; Giacchetti, S. Adv. Drug Deliv. Rev. 2007, 59, 1015.
41. Yang, X. Y.; Downes, M.; Yu, R. T.; Bookout, A. L.; He, W. M.; Straume, M.;
Mangelsdorf, D. J.; Evans, R. M. Cell 2006, 126, 801.
42. Iwata, K.; Aizawa, K.; Sakai, S.; Jingami, S.; Fukunaga, E.; Yoshida, M.; Hamada,
A.; Saito, H. Biol. Pharm. Bull. 2011, 34, 1765.43. Hamdan, A. M.; Koyanagi, S.; Wada, E.; Kusunose, N.; Murakami, Y.;
Matsunaga, N.; Ohdo, S. J. Biol. Chem. 2012, 287, 17224.
44. Martin, C.; Sastre, B.; Mallet, M. N.; Bruguerolle, B.; Brun, J. P.; De Micco, P.;
Gouin, F. Antimicrob. Agents Chemother. 1991, 35, 2602.
45. Bruguerolle, B.; Giaufre, E.; Prat, M. Chronobiol. Int. 1991, 8, 277.
46. Smolensky, M. H.; Peppas, N. A. Adv. Drug Deliv. Rev. 2007, 59, 828.
47. Lin, S. Y.; Kawashima, Y. J. Control Release 2012, 157, 331.
48. Lemmer, B. ChronoPhysiol. Ther. 2012, 2, 9.
49. Escobar, C.; Salgado-Delgado, R.; Gonzalez-Guerra, E.; Osorio, A. T.; Angeles-
Castellanos, M.; Buijs, R. M. Sleep Disorders 2011, 2011.
50. Sukumaran, S.; Almon, R. R.; DuBois, D. C.; Jusko, W. J. Adv. Drug Deliv. Rev.
2010, 62, 904.
51. Mavanji, V.; Billington, C. J.; Kotz, C. M.; Teske, J. A. Neurosci. Biobehav. Rev.
2012, 36, 1015.
52. Cheeseman, J. F.; Winnebeck, E. C.; Millar, C. D.; Kirkland, L. S.; Sleigh, J.;
Goodwin, M.; Pawley, M. D.; Bloch, G.; Lehmann, K.; Menzel, R.; Warman, G. R.
Proc. Natl. Acad. Sci. U.S.A. 2012, 109, 7061.
53. Farrow, S. N.; Solari, R.; Willson, T. M. Expert Opin. Drug Disc. 2012, 7, 535.
